Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 13Leukemia, Biphenotypic, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Accelerated Phase 1Down Syndrome 1Blast Crisis 1

Interventions

Vincristine 3Methotrexate 3Mercaptopurine 3Cytarabine 3Cyclophosphamide 3prednylidene 2pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2azathiopurine 2auricularum 2Thioguanine 2Prednisolone 2Leucovorin 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2deltacortene 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1Radiotherapy 1Radiation 1Prednisone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1Hydrocortisone 1Epirubicin 1Daunorubicin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Down Syndrome × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 90 days × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡